| [1] |
Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6): 567-610.
|
| [2] |
Frank-Raue K, Machens A, Leidig BG, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma[J]. Thyroid, 2013, 23(3): 294-300.
|
| [3] |
Trimboli P, Giovanella L. Serum calcitonin negative medullary thyroid carcinoma: A systematic review of the literature[J]. Clin Chem Lab Med, 2015, 53(10): 1507-1514.
|
| [4] |
Gambardella C, Offi C, Patrone R, et al. Calcitonin negative medullary thyroid carcinoma: A challenging diagnosis or a medical dilemma?[J]. BMC Endocr Disord, 2019, 19(Suppl 1): 45.
|
| [5] |
Chen L, Zhao K, Li F, et al. Medullary thyroid carcinoma with elevated serum CEA and normal serum calcitonin after surgery: A case report and literature review[J]. Front Oncol, 2020, 10: 526716.
|
| [6] |
Trimboli P, Cremonini N, Ceriani L, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: A retrospective multicentre study[J]. Clin Endocrinol (Oxf), 2014, 80(1): 135-140.
|
| [7] |
Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine[J]. Clin Endocrinol (Oxf), 1998, 48(3): 265-273.
|
| [8] |
Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer[J]. Oncologist, 2008, 13(5): 539-547.
|
| [9] |
吴艳乐. 甲状腺癌临床和病理特点的回顾性分析[D]. 武汉: 华中科技大学, 2014.
|
| [10] |
Zhou Q, Yue S, Cheng Y, et al. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin[J]. Exp Toxicol Pathol, 2017, 69(8): 575-579.
|